ANVS ANVS
Company Profile ↓Company Overview
ANVS (ANVS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -30.22% |
| 6 Months: | -28.08% |
| 3 Months: | -17.62% |
| 1 Month: | -2.60% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 63.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - | 0 |
| Operating Income | -186.79K | -306.08K | -241.79K | -583.16K | -2.54M | -1.60M | -3.23M | -2.53M | -2.85M | -5.25M | -5.97M | -6.48M | -9.97M | -9.76M | -14.86M | -7.81M | -7.76M | -4.39M | -6.28M | -6.27M | -7.43M | -18.01M |
| Net Income | -190.90K | -344.70K | -254.12K | -441.59K | -2.31M | -1.01M | -3.20M | -2.52M | -2.85M | -5.23M | -5.94M | -6.43M | -9.74M | -9.54M | -14.72M | -1.07M | -5.02M | -12.64M | -5.54M | -6.22M | -7.26M | -17.61M |
| Diluted EPS | - | - | - | - | - | -0.15 | -0.46 | -0.34 | -0.35 | -0.64 | -0.73 | -0.79 | -1.07 | -1.07 | -1.63 | -0.72 | -0.44 | -0.97 | -0.32 | -0.32 | -0.37 | -0.63 |
| R&D Expense | 6.02K | 6.04K | 2.01K | 66.45K | 856.48K | 718.90K | 2.39M | 1.82M | 1.38M | 2.15M | 4.03M | 4.12M | 7.79M | 8.26M | 13.84M | 6.51M | 5.79M | 2.69M | 5.01M | 5.16M | 6.29M | 16.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.61M | -6.64M | -14.54M | -25.51M | -45.04M | -26.69M | -29.70M |
| Net Income | -990.98K | -5.46M | -14.49M | -25.33M | -56.20M | -24.59M | -28.85M |
| Diluted EPS | - | -0.87 | -1.90 | -3.10 | -6.23 | -2.31 | -1.40 |
| R&D Expense | 776.26K | 3.05M | 8.48M | 16.52M | 38.79M | 20.00M | 25.22M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.12M | 8.12M | 46.00M | 44.10M | 39.97M | 37.12M | 36.02M | 10.21M | 13.93M | 21.08M |
| Total Equity | -7.59M | -8.58M | 7.54M | 44.49M | 42.70M | 38.67M | 34.59M | 28.32M | -7.75M | 9.31M | 16.85M |
| Cash & Equivalents | - | 1.86K | 8.07M | 45.69M | 42.67M | 35.97M | 31.99M | 28.38M | 5.75M | 10.55M | 19.53M |
| Total Liabilities | - | 2.62M | 578.38K | 1.51M | 1.40M | 1.30M | 2.53M | 7.70M | 17.96M | 4.62M | 4.23M |
| Current Liabilities | - | 2.01M | 578.38K | 1.51M | 1.40M | 1.30M | 2.53M | 7.70M | 4.28M | 3.88M | 3.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -476.54K | -3.97M | -9.13M | -17.31M | -39.97M | -21.89M | -25.62M |
| Financing Cash Flow | 443.09K | 12.04M | 46.74M | 4.61K | 17.34M | 26.69M | 34.60M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 11.6% | -72.4% | -32.6% | -89.4% | 725.1% | -264.2% | -171.2% |
| ROCE % | 179.7% | -88.1% | -32.7% | -90.1% | -759.6% | -265.8% | -170.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANVS
$ANVS stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPZEt5bzhRc3RINW5kaUc5NF9ZVHI5MGZxSU83OXBURXVxS0NVWVFvdjFVVTMyb0oyb1R5WFl6MG5OdXV5cGtwVlZMeTdCTHNQWE1QRS0waGxMaVN2QXFrN05pN2s3bGx3T0dfWlItdUplYWtmVUlud1hBWmExU2dHc0h0alBvdVd1MXFKNH…
ANVS Stock Price and Chart — NYSE:ANVS - TradingView
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE4tNTFOcWJucGZyeG4ydkFFZlVCOUdEMTlXaFFGRkdxZzlMUlVFRWZRV25Xc2VEb0NtRGhxN1p2MG9SaUY3TVNGMzFyMmMxeEl6Z3RZRWxYa0F2dw?oc=5" target="_blank">ANVS Stock Price and Chart — NYSE:ANVS</a>&nb…
Annovis Bio (ANVS): Empery Asset Management discloses 5.64% beneficial stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOOUpXc2IyX3kwVUtEUmlpa1NIX3Fxd0tMQVlzdHcwUnBOZzZUMFVranh1ODZJdmFTYlFHQTdweUlFVGhhWTBqb3Bud1g0dzFFdUdId0FXTFRtdEJYZTQzeDRkekxJbG1Zc2F4bHRZN1NHWXNzdlBQcjJTei12aE9LVnVkQ3NrcHdhajNiSU…
Annovis Bio Regains NYSE Listing Compliance - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNRkRDb0hmSHFMcUJPVVFZM1lrRl90aUdJcW10R0lIM1F2SjFoRVM3akRVem84TU0wYnlYZ3A5MWo4ODB4TFZ1dlY4bUZyWHFraXBUeEN3bVVaRXBaMlNBcGNWaGRDSmNtY0RaNXM0d213MXFORUF1WkVCWDBCZnhRTm1LTGpFUHBLMUhzUT…
Annovis Bio director Michael Hoffman buys $142,778 in shares - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQk5Hb21NRDZWd1RNRkd0WnJnS0dGM2ZpY3VKS05DRjhkSU5OTS1hRDVPYVprb0RTTlFKVWR1dHVjcjY3X3VvSjhnSGlEUEMyTDlscWxkZW42Z3d1ZEtadVQ4XzZWOUZWekw4d21aR0dJRm9CSXhIXzN4Z0Zranl2RnJRcXplSUNacWFNcF…
Biotech Annovis prices $15M offer to fund Alzheimer’s, Parkinson’s studies - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxONV9mdm5OYm92dTU1cFUyckNwRWItU0tueDlVdG1sZXhWdHhWS09WWTN5VU93WEgtWDNRMC11dlFudUpod0d1QWRhNW9FRkg4ZTdINVRaYVV4OVRTeVJSVHpod1hqd01vcDVzaXphOTNxU3FuLWdwTFU5U0RLd0RlVUFsVHB2YW5CRjhqcD…
ANVS — Frequently Asked Questions
What is the current share price of ANVS?
As of 2026-08-05 17:25 PDT, ANVS trades at $1.87 on NASDAQ/NYSE. Its 52-week range is $1.59 to $5.10.
What is the P/E ratio of ANVS?
ANVS trades at a trailing price-to-earnings (P/E) ratio of -1.34.
Is ANVS a good stock to buy?
This page provides a data-driven analysis of ANVS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.